Table 4.

Time to radiographic progression

	Abiraterone Acetate + Prednisone
All enrolled patients	131
Radiographic progression event	31 (23.7)
Censored	100 (76.3)
Time to radiographic progression event
Median (95% Cl)	NE (41.4, NE)
Range	(0.0+, 49.8+)
Progression-free rates, n	131
12 months (95% Cl)	0.862 (0.782, 0.915)
24 months (95% Cl)	0.746 (0.645, 0.822)
36 months (95% Cl)	0.691 (0.582, 0.776)
48 months (95% Cl)	0.615 (0.470, 0.732)
Sensitivity analysis*	Abiraterone Acetate + Prednisone
All enrolled patients	131
Radiographic progression event	46 (35.1)
Censored	85 (64.9)
Time to radiographic progression event
Median (95% Cl)	41.4 (27.6, NE)
Range	(0.0+, 49.8+)
Progression-free rates, n	131
12 months (95% Cl)	0.810 (0.723, 0.872)
24 months (95% Cl)	0.665 (0.564, 0.747)
36 months (95% Cl)	0.553 (0.445, 0.648)
48 months (95% Cl)	0.492 (0.367, 0.606)

⁺= censored observation; NE = not estimable.

^*Sensitivity analysis includes events that were not confirmed by a second scan due to patient or physician decision.